Cargando…

Systemic treatment for metastatic prostate cancer

The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Gravis, Gwenaelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Second Military Medical University 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488732/ https://www.ncbi.nlm.nih.gov/pubmed/31061802 http://dx.doi.org/10.1016/j.ajur.2019.02.002

Ejemplares similares

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
por: Pasero, Christine, et al.
Publicado: (2015)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer †
por: Ferrero, Jean-Marc, et al.
Publicado: (2023)

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
por: Jobard, Elodie, et al.
Publicado: (2015)

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
por: Touzani, Rajae, et al.
Publicado: (2019)

FGFR1 and WT1 are markers of human prostate cancer progression
por: Devilard, Elizabeth, et al.
Publicado: (2006)

Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
por: Mari, Roxane, et al.
Publicado: (2022)

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France
por: Houédé, Nadine, et al.
Publicado: (2015)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer
por: Zhao, Janice, et al.
Publicado: (2023)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
por: Rochigneux, Philippe, et al.
Publicado: (2018)

Impact of active surveillance for prostate cancer on the risk of depression and anxiety
por: Sypre, Davidson, et al.
Publicado: (2022)

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
por: Vale, C L, et al.
Publicado: (2018)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Novel therapies are changing treatment paradigms in metastatic prostate cancer
por: Powers, Eric, et al.
Publicado: (2020)

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
por: Vale, Claire L, et al.
Publicado: (2016)

The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey
por: Marino, Patricia, et al.
Publicado: (2022)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Immunotherapy in metastatic prostate cancer
por: Slovin, Susan F.
Publicado: (2016)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
por: Meagher, Margaret F, et al.
Publicado: (2023)

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
por: Mori, Keiichiro, et al.
Publicado: (2021)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
por: Hatano, Koji, et al.
Publicado: (2023)

Patient expectations of benefit from systemic treatments for metastatic prostate cancer
por: Oswald, Laura B., et al.
Publicado: (2019)

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
por: Chen, Kenneth, et al.
Publicado: (2022)

Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up
por: Guerin, Mathilde, et al.
Publicado: (2013)

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
por: Gravis, Gwenaelle, et al.
Publicado: (2023)

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
por: Nussbaum, N, et al.
Publicado: (2016)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Radioisotopes in management of metastatic prostate cancer
por: Raval, Amar, et al.
Publicado: (2016)

Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?
por: Leonel Almeida, Pedro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_huij91bv12vhhpedup4jm530m5